Sequenom Licenses IP for Maternal Urine Tests

Ryan McBride10/30/08

Sequenom (NASDAQ:SQNM), a San Diego-based provider of molecular diagnostics, reports that it has licensed exclusive rights from Monmouth Junction, NJ, diagnostics firm Xenomics (PINK:XNOM) to U.S. and European patents that cover the use of fetal DNA fragments found in a mother’s urine for prenatal diagnostics and research. As Luke discusses in this story, Sequenom is already deep into development of prenatal diagnostics that capture fetal DNA fragments from mothers’ blood samples.